Please rotate the screen for the best
viewing experience. Thank you.

This website was designed with newer technology in mind. Please update your current browser or switch to a recently updated browser. Thank you.

Scroll Down


October 14, 2017

By Geraldine A. Hamilton, PhD President and Chief Scientific Officer
By Geraldine A. Hamilton, PhD President and Chief Scientific Officer


With our partner Cedars-Sinai, we’re creating a new initiative to advance precision medicine

Researchers know that people respond differently to foods, drugs, and chemicals. For example, a medication may be effective in one individual, while it makes another even more ill. Until now, we’ve had no way to test how a diet or a treatment plan would affect a person before administering it to them.

In the effort to provide clinicians with better information about their patients, we’ve announced a program with Cedars-Sinai Medical Center that combines their expertise working with stem cells together with our Organs-on-Chips technology. This Patient-on-a-Chip program holds the potential to advance the field of precision medicine and provide clinicians with a new system that more accurately predicts an individual’s response to foods, medicines, and chemicals.

How it will work

The collaboration leverages innovative stem cell science from Cedars-Sinai and our Human Emulation System, which uses Organs-on-Chips technology to recreate true-to-life biology outside the body. The Human Emulation System creates an environment where cells exhibit an unprecedented level of biological function, and gives researchers the ability to control complex human biology and disease mechanisms that is not possible with other techniques.

Cedars-Sinai scientists can harvest cells from the blood or skin of participating individuals. These cells can then be reprogrammed into induced pluripotent stem cells, which can be made into any organ cell, each bearing the unique genetic fingerprint and characteristics of the individual. This process is particularly useful to recreate cells from organs like the brain, which can’t be sampled from a living individual.

By placing a patient’s cells in Organ-Chips and exposing those cells to a particular drug or series of drugs, clinicians could gain better information about how that individual would respond to treatment, avoiding the risk of administering a drug that may cause harm.


Researchers at Cedars-Sinai can turn cells from a sample of blood or skin into induced pluripotent stem cells, and then reprogram those cells into different organs cells found in the body. These organ cells can then be put on our chips.

“By flowing drugs through Organ-Chips containing a patient’s own cells and tissue, we could predict which treatment is most beneficial for that patient,” said Clive Svendsen, PhD, director of the Cedars-Sinai Board of Governors Regenerative Medicine Institute.

Precision medicine and the power of prediction

The promise of precision medicine is that when a patient is sick, a clinician will be able to develop a tailored treatment plan that takes into account that patient’s unique biology. Better information about how a patient will respond to a disease and to a subsequent treatment will help doctors make more informed decisions.

As we move forward, precision medicine will include preventative measures as well. We foresee a recursive circle of precision medicine that integrates the expertise of doctors and clinicians, data generated by wearables and other devices, the analytic and predictive power of artificial intelligence, together with our living products.


In the recursive circle of precision medicine, the expertise and experiential knowledge of doctors and clinicians will be supplemented with data produced by our living products and the analytic power of AI.

Transforming care

This project holds the potential to change the way diseases are treated. It will also change the way each of us understands and manages our own health by providing deeper insights into our own biology.

“Cedars-Sinai’s world-class stem cell expertise and discovery, combined with Emulate’s pioneering Human Emulation System, is poised to reshape the future of medical care,” said Shlomo Melmed, MB, ChB, executive vice president, Academic Affairs, and dean of the medical faculty at Cedars-Sinai.

To read more about this initiative, see our press release. And to read more about a paper that has been published as part of this partnership, please see: Scientists from Cedars-Sinai and Emulate Produce Human Intestinal Lining That Re-Creates Living Tissue Inside Organ-Chip.